(4-(dimethylamino)butyl) triphenylphosphonium bromide | 83299-97-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(dimethylamino)butyl) triphenylphosphonium bromide
• 英文别名: [4-(Dimethylamino)butyl](triphenyl)phosphanium bromide；4-(dimethylamino)butyl-triphenylphosphanium;bromide
• CAS: 83299-97-2
• 化学式: Br*C₂₄H₂₉NP
• 分子量: 442.379
• InChiKey: LCDIUGAWKLFKKV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.33
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯甲醛 、 (4-(dimethylamino)butyl) triphenylphosphonium bromide 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 生成 N,N-dimethyl-5-phenylpent-4-en-1-amine
  参考文献：
  名称：

  维蒂希反应的立体化学。鏻叶立德中亲核基团的作用

  摘要：

  Les groupes anioniques et nucleophiles sur la chainelaterale desylures de triphenylphosphonium provoquent un deplacement de lastereochimie de l'alcene obtenu vers l'isomere trans dans les 反应 avec des 醛。L'effet est souvent 加上重要的 avec des aldehydes aromatiques qu'avec des aldehydes aliphatiques。氧、羧酸、氨基和酰胺基的取代基研究

  DOI：

  10.1021/ja00287a040
• 作为产物：
  描述：

  [4-(dimethylamino)butyl]triphenylphosphonium bromide hydrobromide 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 0.25h， 以97%的产率得到(4-(dimethylamino)butyl) triphenylphosphonium bromide
  参考文献：
  名称：

  [EN] IONIZABLE CATIONIC LIPIDS
  [FR] LIPIDES CATIONIQUES IONISABLES

  摘要：

  本文披露了新型化合物、包含这些化合物的药物组合物以及相关使用方法。本文所描述的化合物可用作脂质体传递载体，以促进封装的多核苷酸输送到靶细胞并随后转染该靶细胞。在某些实施例中，这些化合物具有一种或多种特性，使得它们相对于其他同类脂质具有优势。

  公开号：

  WO2013149140A1

文献信息

• Antibacterial 16-membered ring macrolides containing olefins at C-20
  申请人：Pfizer Inc.

  公开号：US05677287A1

  公开（公告）日：1997-10-14

  The present invention relates to C-20 olefin derivatives of 16-membered macrolide antibiotics repromicin, rosaramicin, 5-mycaminosyltylonolide, desmycosin, lactenocin, O-demethyllactenocin, 4'-deoxymycaminosyltylonolide and 23-deoxymycaminosyltylonolide, which are useful against bacterial and mycoplasmic pathogens in animals. Also claimed are a pharmaceutical composition of such derivatives and their use in treating bacterial and mycoplasmic infections in animals.

  本发明涉及16元大环内酯类抗生素repromicin、rosaramicin、5-mycaminosyltylonolide、desmycosin、lactenocin、O-demethyllactenocin、4'-deoxymycaminosyltylonolide和23-deoxymycaminosyltylonolide的C-20烯烃衍生物，对动物体内的细菌和支原体病原体有用。还声明了这些衍生物的制药组合物及其在治疗动物体内的细菌和支原体感染中的用途。
• Precatalyzed catalyst compositions, process for preparing epoxy resins, curable compositions, articles resulting from curing the resultant compositions
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0441243A2

  公开（公告）日：1991-08-14

  The process of reacting an epoxy resin with a reactive hydrogen-containing compound or a carboxylic acid anhydride in the presence of a phosphonium catalyst is improved by employing a phosphonium compound having an amino substituent on the cation portion of the phosphonium compound as the catalyst. The invention also concerns precatalyzed epoxy resin compositions, curable compositions and cured compositions.

  本发明改进了在鏻催化剂存在下环氧树脂与活性含氢化合物或羧酸酐反应的工艺，采用了在鏻化合物阳离子部分具有氨基取代基的鏻化合物作为催化剂。本发明还涉及预催化环氧树脂组合物、可固化组合物和固化组合物。
• Ionizable cationic lipids
  申请人：TRANSLATE BIO, INC.

  公开号：US10065919B2

  公开（公告）日：2018-09-04

  Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

  本文公开了新型化合物、包含此类化合物的药物组合物及其相关使用方法。本文所述的化合物是有用的，例如，可用作脂质体递送载体，以促进将封装的多核苷酸递送至靶细胞并随后转染所述靶细胞，在某些实施方案中，这些化合物具有一种或多种特性，使其相对于其他类似分类的脂质具有优势。
• Dantas, T. N. de Castro; Laval, J. P.; Lattes, A., Phosphorus and Sulfur and the Related Elements, 1982, vol. 13, p. 97 - 106
  作者：Dantas, T. N. de Castro、Laval, J. P.、Lattes, A.

  DOI：——

  日期：——
• Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2
  作者：Debjani P. Hudgens、Catherine Taylor、Timothy W. Batts、Manoj K. Patel、Milton L. Brown

  DOI：10.1016/j.bmc.2006.09.010

  日期：2006.12

  The development of new therapies for chronic pain is an area of unmet medical need. Central to pathways of chronic pain is the upregulation of voltage-gated sodium channels. The use of tricyclic antidepressants, which also have sodium channel activity, in chronic pain therapy prompted us to develop novel compounds from this scaffold. Herein, we show that the tricyclic moiety is not needed for effective inhibition of the [H-3]-BTX binding site and sodium currents of hNa(v)1.2. Our lead compound 6, containing a diphenyl amine motif, demonstrated a 53% inhibitory block of Na(v)1.2 currents at 10 mu M, which is greater than 50% increase in current block in comparison to the amitriptyline standard. Altogether our study establishes that the tricyclic motif is unnecessary for hNa(v)1.2 activity and modification of the amine portion is detrimental to sodium channel block. (c) 2006 Elsevier Ltd. All rights reserved.